Baidu
map

IGEM公司获得750000英镑资助,研发针对HER2的抗癌IgE单抗

2019-04-02 不详 MedSci原创

IGEM Therapeutics已获得Innovate UK Biomedical Catalyst Primer Award的750000英镑资助,用于开发针对HER2的新型IgE抗体。

IGEM Therapeutics已获得Innovate UK Biomedical Catalyst Primer Award的750000英镑资助,用于开发针对HER2的新型IgE抗体。

HER2是在临床验证过的癌症抗原,可在多种肿瘤类型上表达,包括乳腺癌卵巢癌癌。

由于目前市售的抗HER2 IgG单抗仅能够治疗表达高水平HER2抗原的癌症患者,而大多数表达中度或低水平HER2的癌症患者不能用抗HER2 IgG单抗治疗。因此,IGEM正在开发与HER2结合的新型人IgE抗体。

IGEM创始人Sophia Karagiannis博士在伦敦国王学院的实验室进行的临床前研究已经证明,与IgG相比,许多IgE抗体具有更高的疗效。该公司还在开发针对叶酸受体α和CSPG-4的抗癌IgE抗体。

IGEM首席执行官Tim Wilson博士评论说:"IGEM是使用IgE抗体治疗癌症的先驱。我们很高兴获得Innovate UK的第二笔资助。我们的目标是利用IgE介导的免疫反应,为严重疾病患者提供新的、安全有效的治疗药物。"

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1647828, encodeId=9510164e828cd, content=<a href='/topic/show?id=2cf3948996' target=_blank style='color:#2F92EE;'>#IGEM公司#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9489, encryptionId=2cf3948996, topicName=IGEM公司)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bfe23501598, createdName=xiaoyeshuang, createdTime=Mon May 13 03:30:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069318, encodeId=e82b20693184d, content=<a href='/topic/show?id=4c22949075' target=_blank style='color:#2F92EE;'>#IgE单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9490, encryptionId=4c22949075, topicName=IgE单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Sat Sep 28 05:30:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300254, encodeId=ebeb1300254f5, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Thu Apr 04 13:30:00 CST 2019, time=2019-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426374, encodeId=27ed14263e4b8, content=<a href='/topic/show?id=032b948ec5' target=_blank style='color:#2F92EE;'>#IgE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9487, encryptionId=032b948ec5, topicName=IgE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0cff4064659, createdName=zhenjiu124, createdTime=Thu Apr 04 13:30:00 CST 2019, time=2019-04-04, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1647828, encodeId=9510164e828cd, content=<a href='/topic/show?id=2cf3948996' target=_blank style='color:#2F92EE;'>#IGEM公司#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9489, encryptionId=2cf3948996, topicName=IGEM公司)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bfe23501598, createdName=xiaoyeshuang, createdTime=Mon May 13 03:30:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069318, encodeId=e82b20693184d, content=<a href='/topic/show?id=4c22949075' target=_blank style='color:#2F92EE;'>#IgE单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9490, encryptionId=4c22949075, topicName=IgE单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Sat Sep 28 05:30:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300254, encodeId=ebeb1300254f5, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Thu Apr 04 13:30:00 CST 2019, time=2019-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426374, encodeId=27ed14263e4b8, content=<a href='/topic/show?id=032b948ec5' target=_blank style='color:#2F92EE;'>#IgE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9487, encryptionId=032b948ec5, topicName=IgE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0cff4064659, createdName=zhenjiu124, createdTime=Thu Apr 04 13:30:00 CST 2019, time=2019-04-04, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1647828, encodeId=9510164e828cd, content=<a href='/topic/show?id=2cf3948996' target=_blank style='color:#2F92EE;'>#IGEM公司#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9489, encryptionId=2cf3948996, topicName=IGEM公司)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bfe23501598, createdName=xiaoyeshuang, createdTime=Mon May 13 03:30:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069318, encodeId=e82b20693184d, content=<a href='/topic/show?id=4c22949075' target=_blank style='color:#2F92EE;'>#IgE单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9490, encryptionId=4c22949075, topicName=IgE单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Sat Sep 28 05:30:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300254, encodeId=ebeb1300254f5, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Thu Apr 04 13:30:00 CST 2019, time=2019-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426374, encodeId=27ed14263e4b8, content=<a href='/topic/show?id=032b948ec5' target=_blank style='color:#2F92EE;'>#IgE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9487, encryptionId=032b948ec5, topicName=IgE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0cff4064659, createdName=zhenjiu124, createdTime=Thu Apr 04 13:30:00 CST 2019, time=2019-04-04, status=1, ipAttribution=)]
    2019-04-04 lqvr
  4. [GetPortalCommentsPageByObjectIdResponse(id=1647828, encodeId=9510164e828cd, content=<a href='/topic/show?id=2cf3948996' target=_blank style='color:#2F92EE;'>#IGEM公司#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9489, encryptionId=2cf3948996, topicName=IGEM公司)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bfe23501598, createdName=xiaoyeshuang, createdTime=Mon May 13 03:30:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069318, encodeId=e82b20693184d, content=<a href='/topic/show?id=4c22949075' target=_blank style='color:#2F92EE;'>#IgE单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9490, encryptionId=4c22949075, topicName=IgE单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Sat Sep 28 05:30:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300254, encodeId=ebeb1300254f5, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Thu Apr 04 13:30:00 CST 2019, time=2019-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426374, encodeId=27ed14263e4b8, content=<a href='/topic/show?id=032b948ec5' target=_blank style='color:#2F92EE;'>#IgE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9487, encryptionId=032b948ec5, topicName=IgE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0cff4064659, createdName=zhenjiu124, createdTime=Thu Apr 04 13:30:00 CST 2019, time=2019-04-04, status=1, ipAttribution=)]
    2019-04-04 zhenjiu124
Baidu
map
Baidu
map
Baidu
map